Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APT-1011 in Eosinophilic Esophagitis
NCT04281108Phase 3Completed
- Sponsor
- Ellodi Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of fluticasone propionate in eosinophilic esophagitis (EoE), sponsored by Ellodi Pharmaceuticals. Started Jan 2020; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04281108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281108.